Research Article
E-ISSN : 3048-1368

Volume 02, Issue No. 08. 2024
P-ISSN : 3048-1376

The International Journal of Medical Science and Health Research



Effect of Laser Photocoagulation and Bevacizumab Intravitreal in Proliferative Diabetic Retinopathy

[1] Lanny, [1] Lucky

[1] Faculty of Medicine, Tarumanagara University, Special Region of Jakarta, Indonesia

Correspondence : drlucky201984@gmail.com

Article History :

Received date : 2024/04/11
Revised date : 2024/05/03
Accepted date : 2024/06/19
Published date : 2024/07/04

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

E-ISSN :

ISSN 3048-1368

P-ISSN :

ISSN 3048-1376

ABSTRACT

Background: The literature on the management of proliferative diabetic retinopathy (PDR) has evolved significantly over the past decade, particularly with the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies alongside traditional laser photocoagulation techniques. **Literature Review:** The literature on the management of proliferative diabetic retinopathy (PDR) highlights a significant evolution in treatment strategies, particularly with the integration of anti-VEGF therapies alongside traditional laser photocoagulation. The foundational work by Arevalo (2013) establishes intravitreal bevacizumab as an effective treatment for retinal and iris neovascularization, suggesting its potential as an alternative or adjunctive therapy to conventional methods. This study emphasizes the necessity of continuous monitoring and the possibility of recurrence of neovascularization, reinforcing the importance of laser photocoagulation as a cornerstone in PDR management. **Conclusion:** In conclusion, the literature reflects a dynamic interplay between traditional laser therapies and innovative pharmacological approaches in the management of PDR. There is a clear trend towards integrative strategies that aim to enhance patient outcomes, emphasizing the importance of personalized treatment plans that consider both the efficacy and safety of available interventions.

Keyword: Effect, Laser Photocoagulation, Bevacizumab Intravitreal, Proliferative Diabetic Retinopathy

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The literature on the management of proliferative diabetic retinopathy (PDR) has evolved significantly over the past decade, particularly with the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies alongside traditional laser photocoagulation techniques. The early work of Arevalo (2013) establishes a foundational understanding of the utility of intravitreal bevacizumab in treating PDR, highlighting its effectiveness in promoting regression of retinal and iris neovascularization ((Fernando Arevalo, 2013)). This article sets the stage for subsequent explorations into the role of anti-VEGF agents in the context of surgical interventions, particularly in relation to intraoperative complications.

Building on Arevalo's findings, Sato et al. (2013) investigate the implications of preoperative intravitreal bevacizumab on surgical outcomes in PDR patients undergoing vitrectomy. Their study reveals that the administration of bevacizumab prior to surgery can significantly reduce intraoperative bleeding, thereby improving the feasibility and safety of the surgical procedure ((Sato et al., 2013)). This research underscores the potential of integrating pharmacotherapy with surgical techniques, suggesting a shift toward more comprehensive treatment protocols.

Further expanding on the efficacy of anti-VEGF therapy, Alagöz et al. (2016) focus on the specific challenges posed by vitreous hemorrhage (VH) in diabetic retinopathy. They demonstrate that bevacizumab not only facilitates the resolution of VH but also enhances the effectiveness of panretinal photocoagulation, which is traditionally the gold standard for PDR treatment ((Alagöz et al., 2016)). This study emphasizes the importance of addressing VH as a significant barrier to effective treatment, reinforcing the need for a multifaceted approach in managing PDR.

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

In a systematic review, Mozetic et al. (2017) critically assess the existing literature on diabetic retinopathy treatments, reaffirming that laser photocoagulation remains the primary modality for managing PDR. However, they advocate for further research into the combined use of photocoagulation and anti-VEGF therapies, noting the potential for improved visual outcomes despite the inherent risks associated with each treatment modality ((Mozetic et al., 2017)). This review highlights the necessity of balancing efficacy with safety, particularly in light of the side effects associated with laser treatments.

Hu et al. (2021) contribute to this discourse by questioning whether newer anti-VEGF agents, such as aflibercept, could surpass traditional treatments like vitrectomy combined with panretinal photocoagulation in restoring vision for PDR patients. Their systematic review protocol aims to clarify the comparative effectiveness of these interventions, reflecting the ongoing debate within the field regarding the best therapeutic strategies for PDR management ((Hu et al., 2021)).

Most recently, Zhao et al. (2023) explore the outcomes of combining aflibercept with photocoagulation in high-risk PDR cases, further emphasizing the evolving landscape of treatment options. Their findings suggest that while anti-VEGF therapies can provide significant benefits, the combination with traditional methods may yield the most favorable results in terms of safety and effectiveness ((Zhao et al., 2023)).

Overall, the body of literature reflects a dynamic interplay between traditional laser therapies and innovative pharmacological approaches, with a clear trend towards integrative strategies aimed at optimizing patient outcomes in the management of proliferative diabetic retinopathy.

LITERATURE REVIEW

The article by Arevalo (2013) provides a comprehensive examination of the efficacy of intravitreal bevacizumab as an anti-vascular endothelial growth factor

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

(VEGF) therapy in managing complications associated with proliferative diabetic retinopathy (PDR). The author emphasizes the critical role of photocoagulation in the standard treatment of PDR, highlighting its ability to reduce the risk of severe vision loss. However, the article also posits that intravitreal bevacizumab may serve as a viable alternative or adjunctive therapy, particularly in cases where traditional photocoagulation may not be feasible or sufficient.

Arevalo reports on the mechanism of action of bevacizumab, which involves the inhibition of VEGF, a key factor in the pathogenesis of neovascularization in PDR. The article details clinical outcomes that demonstrate significant regression of retinal and iris neovascularization following bevacizumab treatment. This regression is particularly noteworthy as it suggests a potential for not only stabilizing vision but also improving the overall retinal health of patients suffering from PDR.

The critical evaluation of the material reveals that while the findings are promising, the article also raises essential considerations regarding the long-term efficacy and safety of intravitreal bevacizumab. Arevalo discusses the potential for recurrence of neovascularization after treatment, which underscores the necessity for ongoing monitoring and possibly repeated interventions. Furthermore, the author notes that while bevacizumab may provide rapid results, it does not replace the need for photocoagulation, which remains a cornerstone in the management of PDR.

The article titled "Early Vitreous Hemorrhage after Vitrectomy with Preoperative Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy" by Sato et al. (2013) delves into the implications of utilizing intravitreal bevacizumab (IVB) as a preoperative adjunct in the surgical management of proliferative diabetic retinopathy (PDR). The study is grounded in the understanding that PDR is characterized by retinal neovascularization, a process significantly driven by vascular endothelial growth factor (VEGF).

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The authors highlight the established role of panretinal laser photocoagulation as the primary treatment modality for PDR, which directly targets and reduces VEGF levels, thereby addressing the neovascularization.

A critical aspect of the article is its exploration of the dual approach combining laser photocoagulation with IVB. The authors present evidence suggesting that administering IVB prior to vitrectomy may mitigate intraoperative bleeding, which is a common complication during surgical interventions for PDR. This is particularly relevant given that excessive bleeding can complicate the surgical procedure and negatively impact visual outcomes. The article references a clinical trial indicating that IVB administered one week before surgery could reduce the incidence of early postoperative hemorrhage, providing a compelling argument for its use in clinical practice.

However, the authors also acknowledge the mixed outcomes reported in various studies regarding the efficacy of IVB pretreatment in influencing postoperative vitreous hemorrhage rates. This critical evaluation underscores the need for further research to establish a consensus on the benefits of IVB in this context. The article effectively emphasizes the complexity of treatment strategies for PDR and the necessity of considering both the potential advantages and limitations of IVB as an adjunct to traditional laser therapy.

The article titled "The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects" by Alagöz et al. (2016) provides a thorough examination of the role of intravitreal bevacizumab in the management of vitreous hemorrhage (VH) associated with proliferative diabetic retinopathy (PDR). The authors effectively contextualize the significance of diabetic retinopathy as a leading cause of vision loss among working-age adults in developed countries, emphasizing the critical nature of timely and effective treatment options.

The article outlines the pathophysiology of diabetic

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

retinopathy, noting that the release of angiogenic mediators such as vascular endothelial growth factor (VEGF) in response to retinal ischemia leads to the formation of neovascular structures. These structures are implicated in the development of complications such as vitreous hemorrhage and tractional retinal detachment, which complicate the application of panretinal photocoagulation (PRP), the established treatment for PDR. The authors present a compelling rationale for the use of bevacizumab, a humanized monoclonal anti-VEGF antibody, highlighting its ability to inhibit all isoforms of VEGF and induce rapid regression of neovascularization.

A critical evaluation of the study reveals that while the authors provide substantial evidence for the efficacy of intravitreal bevacizumab in promoting the resolution of vitreous hemorrhage, the article could benefit from a more detailed discussion on the comparative effectiveness of bevacizumab versus traditional therapies such as PRP. Additionally, the long-term outcomes of bevacizumab treatment in terms of visual acuity and potential complications associated with repeated intravitreal injections warrant further exploration.

The study's findings indicate that intravitreal bevacizumab not only facilitates the resolution of hemorrhage but may also enhance the effectiveness of subsequent PRP treatments. This dual benefit positions bevacizumab as a viable option for managing VH in patients with PDR, particularly in cases where immediate PRP is not feasible due to the presence of hemorrhage.

The article "What do Cochrane systematic reviews say about diabetic retinopathy?: O que as revisões sistemáticas da Cochrane dizem sobre retinopatia diabética?" by Mozetic et al. (2017) provides a comprehensive analysis of the efficacy of laser photocoagulation and bevacizumab intravitreal injections in the treatment of proliferative diabetic retinopathy (PDR). The authors meticulously reviewed existing studies while accounting for potential biases in

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

execution, which is crucial for ensuring the validity of their findings.

One of the significant insights from the review is the heterogeneity observed among the trials, indicated by an I^2 statistic greater than 50%. This suggests that the results from different studies varied considerably, which complicates the synthesis of evidence and the drawing of definitive conclusions regarding treatment efficacy. The authors noted that long-term follow-up data lacked consistency; however, they highlighted a specific study that demonstrated a 20% reduction in the risk of losing 15 letters or more in visual acuity over five years with laser photocoagulation.

The article emphasizes that laser photocoagulation remains the preferred treatment for PDR despite its side effects, such as diminished field of view and impaired night vision. This is an important consideration for clinicians when weighing treatment options. The authors advocate for further research into combining photocoagulation with anti-angiogenic treatments, specifically vascular endothelial growth factor (VEGF) inhibitors, to potentially enhance patient outcomes while mitigating the adverse effects associated with laser treatment.

The review also examined 18 randomized clinical trials involving 1,005 patients, revealing that while bevacizumab treatment was associated with improved visual acuity after 12 months, there were significant concerns regarding the reliability of the estimates, particularly due to the high risk of bias in seven studies and dubious risk in others. This raises important questions about the robustness of the evidence supporting bevacizumab's effectiveness in treating PDR.

The article titled "Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis" by Hu et al. (2021) addresses a critical aspect of the management of proliferative diabetic retinopathy (PDR), a leading cause of severe vision loss in individuals with diabetes. The authors highlight the evolution of treatment

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

modalities, from traditional vitrectomy to the advent of intravitreal therapies targeting vascular endothelial growth factor (VEGF), which have revolutionized the approach to diabetic eye diseases.

The article effectively outlines the historical context of PDR treatment, emphasizing that vitrectomy has been the standard for addressing complications such as vitreous hemorrhage. However, the authors note that despite advancements in surgical techniques, the risk of complications persists. This acknowledgment of the limitations of surgical intervention sets the stage for discussing the emerging role of intravitreal aflibercept, a VEGF inhibitor, which has shown promise in managing diabetic macular edema and may offer benefits for PDR patients as well.

The authors critically evaluate the current evidence surrounding the efficacy of intravitreal aflibercept compared to the traditional approach of vitrectomy with panretinal photocoagulation (PRP). They point out that while recent studies suggest that monthly anti-VEGF treatments can mitigate the severity and progression of diabetic retinopathy, the comparative effectiveness in terms of vision restoration between these two treatment modalities remains contentious. The inconsistency in findings from randomized cohort studies underscores the need for a systematic review to consolidate evidence and clarify the therapeutic landscape for PDR.

Furthermore, the article's proposal for a systematic review and meta-analysis is a prudent step toward addressing the existing knowledge gap. By focusing on level I evidence, the authors aim to provide a robust comparison that could inform clinical decision-making and potentially reshape treatment protocols for PDR. This approach is particularly relevant given the ongoing debate regarding the optimal management strategy for patients suffering from this debilitating condition.

The article "Retinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy" by Zhao et al. (2023) provides a

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

comprehensive analysis of the treatment modalities for high-risk proliferative diabetic retinopathy (PDR), particularly focusing on the effectiveness of aflibercept in combination with panretinal photocoagulation (PRP). The authors highlight the significant public health concern posed by diabetic retinopathy, which can lead to preventable blindness, especially among working-aged adults.

The article begins by establishing the diagnostic criteria for high-risk PDR, emphasizing the importance of recognizing optic disk neovascularization and the presence of preretinal or vitreous hemorrhage. The authors effectively reference the Diabetic Retinopathy Study, which advocates for immediate PRP as a standard treatment for high-risk cases. This sets a solid foundation for understanding the urgency and necessity of effective intervention in this patient population.

A critical evaluation of the findings indicates that while PRP has long been recognized for its efficacy, the introduction of anti-VEGF agents, particularly aflibercept, presents a compelling alternative or adjunctive treatment. The authors note that previous studies, including the Diabetic Retinopathy Clinical Research Network Protocol S, demonstrate that intravitreal injections of ranibizumab can yield better visual acuity outcomes compared to PRP alone. This suggests a potential paradigm shift in treatment strategies, highlighting the need for clinicians to consider both the visual and economic implications of these therapies.

Moreover, the article discusses the safety and effectiveness of anti-VEGF therapies, indicating that they may be comparable or even superior to traditional PRP. The authors suggest that a combination of both treatments could potentially offer the best outcomes for patients suffering from high-risk PDR. This is particularly relevant as it underscores the evolving nature of diabetic retinopathy management, where personalized treatment plans may enhance patient outcomes.

CONCLUSION

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The literature on the management of proliferative diabetic retinopathy (PDR) highlights a significant evolution in treatment strategies, particularly with the integration of anti-VEGF therapies alongside traditional laser photocoagulation. The foundational work by Arevalo (2013) establishes intravitreal bevacizumab as an effective treatment for retinal and iris neovascularization, suggesting its potential as an alternative or adjunctive therapy to conventional methods. This study emphasizes the necessity of continuous monitoring and the possibility of recurrence of neovascularization, reinforcing the importance of laser photocoagulation as a cornerstone in PDR management.

Sato et al. (2013) further explore the implications of preoperative bevacizumab on surgical outcomes, indicating that its administration can significantly reduce intraoperative bleeding during vitrectomy. This finding supports the integration of pharmacotherapy with surgical techniques, suggesting a shift toward comprehensive treatment protocols that enhance the safety and feasibility of surgical interventions.

The challenges posed by vitreous hemorrhage (VH) in diabetic retinopathy are addressed by Alagöz et al. (2016), who demonstrate that bevacizumab not only aids in the resolution of VH but also enhances the effectiveness of panretinal photocoagulation. Their findings underscore the need for multifaceted approaches in managing PDR, particularly in cases where traditional treatments may be hindered by complications such as VH.

Mozetic et al. (2017) provide a systematic review that reinforces the efficacy of laser photocoagulation while advocating for further research into the combined use of photocoagulation and anti-VEGF therapies. Their analysis highlights the necessity of balancing treatment efficacy with safety, particularly given the potential side effects associated with laser treatments.

Hu et al. (2021) contribute to the ongoing discourse by questioning the comparative effectiveness of newer anti-VEGF agents, such as aflibercept, versus traditional

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

treatments like vitrectomy combined with panretinal photocoagulation. Their systematic review protocol aims to clarify these therapeutic strategies, reflecting the complexity and evolving nature of PDR management.

Zhao et al. (2023) explore the outcomes of combining aflibercept with photocoagulation in high-risk PDR cases, suggesting that this integrative approach may yield favorable results in terms of safety and effectiveness. Their findings reinforce the notion that while anti-VEGF therapies provide significant benefits, the combination with traditional methods may optimize patient outcomes.

In conclusion, the literature reflects a dynamic interplay between traditional laser therapies and innovative pharmacological approaches in the management of PDR. There is a clear trend towards integrative strategies that aim to enhance patient outcomes, emphasizing the importance of personalized treatment plans that consider both the efficacy and safety of available interventions.

REFERENCES

1. Fernando Arevalo, J., 2013. Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy. ncbi.nlm.nih.gov
2. Sato, T., Morita, S., Bando, H., Sato, S., Ikeda, T., & Emi, K., 2013. Early Vitreous Hemorrhage after Vitrectomy with Preoperative Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy. ncbi.nlm.nih.gov
3. Alagöz, C., Yıldırım, Y., Kocamaz, M., Baz, Ökkeş, Çiçek, U., Çelik, B., İbrahim Demirkale, H., Taylan Yazıcı, A., & Taşkapılı, M., 2016. The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects. ncbi.nlm.nih.gov
4. Mozetic, V., Pozzetti Daou, J., Luiza Cabrera Martimbianco, A., & Riera, R., 2017. What do Cochrane systematic reviews say about diabetic

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

retinopathy?: O que as revisões sistemáticas da Cochrane dizem sobre retinopatia diabética?. ncbi.nlm.nih.gov

5. Hu, Y., Shen, J., & Peng, Y., 2021. Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis. ncbi.nlm.nih.gov
6. Zhao, H., Wang, J., Li, S., Bao, Y., Zheng, X., Tao, Y., & Wang, H., 2023. Retinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy. ncbi.nlm.nih.gov

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved